A 5-lipoxygenase inhibitor, FR110302, suppresses airway hyperresponsiveness and lung eosinophilia induced by Sephadex particles in rats.
To study the role of chemical mediators in airway hyperresponsiveness and simultaneous eosinophilia, we examined effects of a potent 5-lipoxygenase inhibitor FR110302 and those of prednisolone, indomethacin, platelet-activating factor (PAF) antagonist (RP-59227) and leukotriene C4 (LTC4) antagonist (ONO-1078) on airway hyperresponsiveness and lung eosinophilia induced by Sephadex particles. Sephadex G200 particles (2.5 mg/kg) were injected intravenously to rats and 3 days later the airway hyperresponsiveness to acetylcholine (ACh) and the eosinophilia in the bronchoalveolar lavage (BAL) fluids were observed. FR110302 (10 mg/kg b.i.d.p.o.) significantly suppressed both of these indicators of asthma. The amounts of immunoreactive LTB4,C4 (i-LTB4, C4) in the BAL fluid were measured by radioimmunoassay. The amounts of i-LTB4,C4 in the FR110302-treated rats were significantly less compared with that in the Sephadex-injected controls. Prednisolone completely inhibited the airway hyperresponsiveness. PAF antagonist and LTC4 antagonist partially inhibited the airway hyperresponsiveness, and indomethacin had no effect. The results indicate that 5-lipoxygenase products play important roles in the Sephadex-induced airway hyperresponsiveness and lung eosinophilia in rats.
Asano
M
M
Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd. Tsukuba Research Laboratories, Ibaraki, Japan.
Inamura
N
N
Nakahara
K
K
Nagayoshi
A
A
Isono
T
T
Hamada
K
K
Oku
T
T
Notsu
Y
Y
Kohsaka
M
M
Ono
T
T
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D016535:Bronchial Hyperreactivity / Q000517:prevention & control*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002867:Chromones / Q000494:pharmacology; D003911:Dextrans; D006168:Guinea Pigs; D006801:Humans; D007082:Ileum / Q000187:drug effects; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D007975:Leukotriene B4 / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D008297:Male; D008863:Microspheres; D009284:Naphthols / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D011239:Prednisolone / Q000494:pharmacology; D011657:Pulmonary Eosinophilia / Q000139:chemically induced / Q000517:prevention & control*; D011725:Pyridines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013189:SRS-A / Q000037:antagonists & inhibitors / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology
D002867:Chromones; D003911:Dextrans; D016859:Lipoxygenase Inhibitors; D009284:Naphthols; D010972:Platelet Activating Factor; D011725:Pyridines; D011804:Quinolines; D013189:SRS-A; D013844:Thiazoles; C065022:RP 59227; C074243:FR 110302; D007975:Leukotriene B4; C025614:sephadex; D011239:Prednisolone; D000109:Acetylcholine; C047681:pranlukast; D007213:Indomethacin